Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01438073 · ClinicalTrials.gov registry record · Phase 1
Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT01438073: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT01438073 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 96 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01438073, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
The investigators are looking for subjects to complete a study on the role of kisspeptin in the reproductive system. Kisspeptin is a naturally occurring hormone in humans that tells the body to produce other reproductive hormones. However, giving someone a continued amount of kisspeptin over a period of time can have the opposite effect and tell the body to, for a short time, stop making hormones needed for reproduction. By giving 24-hour infusions of kisspeptin, the investigators hope to learn more about the role kisspeptin has in the way bodies function normally and the role it has in conditions that affect the reproductive system.
Interventions
- DRUG kisspeptin 112-121
- DRUG GnRH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2011-09 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01438073
The ClinicalTrials.gov registry entry for NCT01438073 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which kisspeptin 112-121 is the first listed.
NCT01438073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01438073 about?
NCT01438073 is a clinical study titled "Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling". The investigators are looking for subjects to complete a study on the role of kisspeptin in the reproductive system. Kisspeptin is a naturally occurring hormone in humans that tells the body to produce other reproductive hormones. However, giving someone a continued amount of kisspeptin over a perio...
What is the current status of trial NCT01438073?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2011-09. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01438073?
The interventions under investigation include: kisspeptin 112-121 (DRUG), GnRH (DRUG).
Who is sponsoring clinical trial NCT01438073?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.